Headlines about Viveve Medical (NASDAQ:VIVE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viveve Medical earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.7330671542808 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern’s analysis:

A number of equities analysts recently weighed in on the stock. ValuEngine downgraded shares of Viveve Medical from a “buy” rating to a “hold” rating in a research note on Monday, July 30th. Craig Hallum downgraded shares of Viveve Medical from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Viveve Medical presently has a consensus rating of “Buy” and an average target price of $9.20.

NASDAQ VIVE traded down $0.03 during mid-day trading on Friday, reaching $3.11. 2,734 shares of the stock were exchanged, compared to its average volume of 213,317. Viveve Medical has a one year low of $1.60 and a one year high of $6.00. The company has a market capitalization of $110.53 million, a PE ratio of -1.47 and a beta of -0.30. The company has a quick ratio of 4.00, a current ratio of 4.41 and a debt-to-equity ratio of 3.42.

Viveve Medical (NASDAQ:VIVE) last announced its earnings results on Thursday, August 9th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%. The business had revenue of $5.53 million during the quarter, compared to the consensus estimate of $4.97 million. equities analysts expect that Viveve Medical will post -1.51 earnings per share for the current fiscal year.

About Viveve Medical

Viveve Medical, Inc engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

Recommended Story: Diversification For Individual Investors

Insider Buying and Selling by Quarter for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.